IJARSCT

International Journal of Advanced Research in Science, Communication and Technology

International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal

ISSN: 2581-9429

Volume 5, Issue 2, July 2025

Impact Factor: 7.67

Polymeric Ofloxacin Nanocarriers for Sustained Ocular Delivery: Advances in Formulation Strategies and Bio-availability Enhancement

Bhawana Kumari, Dr. Ram Babu Sharma, Dr. Sakshi, Ms. Anjali Dixit

Himalayan Institute of Pharmacy, Kala Amb, Himachal Pardesh, India

Abstract: *Ocular bacterial infections—ranging from conjunctivitis to sight-threatening keratitis and postoperative endophthalmitis continue to impose a heavy global burden, with World Health Organization estimating three to five million new cases of visual impairment yearly. Conventional 0.3 % ofloxacin eye-drops, although inexpensive and broad-spectrum, rarely deliver more than 5 % of the instilled dose to the anterior chamber because of rapid tear turnover, blink-induced shear, and the formidable tight junctioned corneal epithelium. Encapsulation efficiencies routinely exceed 65 %, and optimised nano-in-gel hybrids achieve six-fold increasesaqueous-humour exposure and two-day suppression of Staphylococcus aureus and Pseudomonas aeruginosa growth in rabbit keratitis models. Sub-therapeutic exposure necessitates dosing every two to four hours, undermines adherence, fosters antimicrobial resistance. Regulatory momentum is building: the U.S. FDA's 2022 nanomaterial guidance and the EMA's 2023 reflection paper call for comparative physicochemical characterisation, sterile process control, and long term ocular safety datasets, yet remain agnostic on specific testing matrices, underscoring a need for harmonised global standards. Key translational gaps persist—most notably six-month primate toxicology, pragmatic effectiveness trials against high-frequency drops, and solvent-footprint reduction through green antisolvent technologies such as super-critical CO_2. Artificial-intelligence-guided design experiments and time process analytical technology promise to shrink formulation timelines, reduce reagent consumption, and tailor nano-architectures to pathogen-specific pharmacodynamic targets. Looking ahead, polymeric ofloxacin nanocarriers could underpin once-daily eye-drops, week-long drug-eluting contact lenses, thus redefining first-line ocular antibiotic therapy, alleviating patient-burdened dosing schedules, and curbing resistance by maintaining supra-MIC exposure profiles. safety, sustainability, and regulatory convergence , these smart nanocarriers will shift ocular pharmacotherapy.*

Keywords: Ofloxacin; ocular drug delivery; polymeric nanoparticles; sustained release; bioavailability; microfluidics

I. INTRODUCTION

Ocular drug delivery need to develop sophisticated ocular formulations arises from the prevalence of sight-threatening diseases and the importance of preserving vision for a patient's quality of life. Understanding the backdrop—encompassing the structure of the eye, protective barriers such as tear film and blinking, and deeper layers like the cornea—is pivotal for formulating effective treatments. The eye's natural defense mechanisms are evolutionarily designed to keep foreign substances away, which unfortunately includes many therapeutics that might be needed to treat various ocular conditions. As a result, topical eye drops, the most common drug delivery form, often fail to achieve optimal penetration or retention, thus limiting therapeutic efficacy. In recent years, pharmaceutical and biomedical research has devoted considerable attention to novel delivery systems that can address these shortcomings. Although topical antibiotics remain the first line of defence against ocular bacterial infections, therapeutic outcomes are constrained by the eye's highly evolved protective architecture. A typical 30-µL instilled drop exceeds the physiologic tear volume threefold; reflex blinking and nasolacrimal drainage therefore expel nearly 90 percent of the dose within

DOI: 10.48175/IJARSCT-28376

the first minute, while the negatively charged mucin network and the lipophilic, tight-junctioned corneal epithelium deter penetration of hydrophilic molecules (Cao et al., 2023).

The cornea is the transparent, dome-shaped surface forming the anterior-most structure of the eye. It consists of multiple layers: the epithelium, Bowman's layer, stroma, Descemet's membrane, and endothelium. Corneal epithelial cells possess tight junctions that tightly regulate entry of substances, including drugs, into deeper tissues. The cornea's unique arrangement of collagen fibrils in the stroma contributes not only to its transparency but also to its structural integrity. Meanwhile, the endothelium maintains corneal dehydration to preserve its refractive properties. Surrounding the cornea is the conjunctiva, a thin membrane that lines the inner surface of the eyelids and extends across the sclera. Richly vascularized, the conjunctiva's capillaries help supply nutrients but also allow for rapid clearance of drugs through systemic circulation, thereby complicating local drug retention.

These anatomical features underscore the first set of hurdles for ocular drug delivery: each layer, from the corneal epithelium to the retinal pigmented epithelium, is designed to protect the internal environment. Understanding these layers provides context for appreciating how specialized formulations must be tailored to overcome or bypass these barriers to achieve therapeutic concentrations where needed.

Because of these structural complexities, topically applied medications often have limited penetration. Hence, the typical eye drop can deliver only a small fraction of its active ingredient into the internal structures of the eye. Even when the drug manages to penetrate the cornea, rapid clearance via the conjunctival vasculature and tear drainage system can dramatically reduce its residence time. Such challenges necessitate the continuous search for novel strategies in ocular pharmacology and pharmaceutics to improve drug retention and efficacy.

Evidence from tear-film fluorophotometry and gamma scintigraphy shows that less than 2 µL of the instilled fluid actually contacts the epithelial surface after 60 s (Gupta, Aqil, & Khar, 2022). For ofloxacin, whose moderate log P (≈ 1.8) renders it insufficiently lipophilic for passive corneal diffusion yet susceptible to epithelial efflux pumps, the result is sub-therapeutic anterior-chamber levels that fall below the MIC for *Pseudomonas aeruginosa* and *Staphylococcus aureus* within 30–45 min, necessitating dosing every 2–3 h (Singh, 2022). Poor adherence, coupled with fluctuating concentrations, fosters microbial resistance and treatment failure (Sharma & Jadhav, 2021).

Polymeric nanocarriers offer a multi-pronged counter-strategy. By encapsulating the drug in a biodegradable matrix, they shield it from environmental degradation, enable controlled diffusion through the polymer network, and—in the case of cationic or mucoadhesive shells—form electrostatic or hydrogen-bonding interactions with the mucin layer, resisting instantaneous tear wash-out (Bisen et al., 2024).

Due to complex anatomy and physiology of eye delivery of drugs to eye has become challenging task that limit the entry of

Over the past decade, biodegradable polymeric nanocarriers—principally poly(lactic-co-glycolic acid), polycaprolactone, chitosan, hyaluronic acid, and smart stimuli-responsive copolymers—have emerged as a transformative platform that protects ofloxacin from hydrolysis, prolongs precorneal residence through muco-adhesion, negotiates epithelial barriers via size-guided uptake, and sustains zero-order release for 8–24 h after a single instillation. Particles sized between 80 and 200 nm can exploit transcellular endocytosis and limited paracellular routes while remaining filter-sterilisable, a regulatory imperative for ophthalmic preparations (Pathak & Singh, 2025). The addition of in-situ gelling triggers—whether ion-activated gellan gum that cross-links in the presence of divalent cations, or thermo-responsive PNIPAM-g-PEG that gels at ocular-surface temperature—converts a mobile instillate into a viscoelastic depot, further prolonging residence without compromising vision through excessive turbidity (Rao & Bandyopadhyay, 2023).

Continuous-flow microfluidic manufacturing now yields particles with <5 % diameter coefficient of variation at clinical scale while meeting sterile-filtration or closed-loop γ-irradiation requirements, positioning these formulations for cGMP adoption. Ion-activated gellan gums, thermo-responsive PNIPAM-g-PEG scaffolds, and dual-grafted chitosan-PEG shells provide complementary levers to balance viscosity, optical clarity, and patient

This review focuses on the goals listed below:-

To summarise the physiological barriers and pharmacokinetic pitfalls that any ocular nano-formulation must overcome.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 2, July 2025 Impact Factor: 7.67

To catalogue the polymer chemistries, fabrication techniques, and critical quality attributes that define a successful ofloxacin nanocarrier.

To critically appraise biological performance data linking formulation variables to antibacterial efficacy, corneal permeation, and safety.

To analyse translational and regulatory hurdles and propose a roadmap—for instance, leveraging AI-guided design of experiments and continuous sterile microfluidic production—to accelerate bench-to-clinic translation.

II. PHYSIOLOGICAL AND ANATOMICAL BARRIERS TO OCULAR DRUG DELIVERY

From a formulation perspective, the eye is arguably the most formidable non-parenteral delivery site in the body. Pre-corneal factors dominate the initial loss: basal tear secretion averages 1–2 µL min^{-1}, but reflex tearing after instillation spikes several-fold, diluting the drug and promoting nasolacrimal drainage into the inferior meatus where systemic absorption rather than ocular bio-availability occurs (Patravale & Kulkarni, 2023). The mechanical shear of blinking, typically 15–20 cycles per minute, spreads and thins the tear film, producing convective clearance. Surface pH (≈ 7.4) and protein content can also destabilise labile molecules.

Once a nanoparticle adheres to the corneal surface it faces the epithelium, a lipophilic barrier only 50–60 µm thick yet formidable due to tight junctions that restrict paracellular movement of molecules larger than 500 Da (Malik & Chauhan, 2023). Beneath, the hydrophilic stroma containing densely packed collagen lamellae impedes lipophilic diffusion, creating a polarity mismatch that frustrates most small molecules. Two additional vascular barriers—the blood–aqueous and blood–retinal—further restrict posterior segment access, explaining why topical dosing is generally ineffective for vitreous infections unless permeation enhancers or nanoformulations are used (Cao et al., 2023).



One of the most immediate obstacles to ocular drug delivery is the tear film. This multi-layered structure comprises three main components: a mucin layer, an aqueous layer, and a lipid layer. Each layer performs crucial functions to maintain corneal hydration, optical clarity, and protection against pathogens. Tear fluid is not static; it is continuously

DOI: 10.48175/IJARSCT-28376

replenished and drained through the nasolacrimal duct. This dynamic environment can effectively wash away exogenous substances—be they pathogens or topically administered drugs—within minutes.

The typical human blink rate of approximately 10 to 20 times per minute (depending on individual and environmental factors) further complicates drug retention. Blinking mechanically redistributes tear fluid across the corneal surface, ensuring even lubrication but also leading to rapid dilution or displacement of administered drugs. When a patient instills eye drops, blinking can force the solution to the lacrimal punctum, leading to drainage into the nasal cavity and reducing the effective concentration of the drug on the ocular surface. Therefore, the tear film and blinking act synergistically as a sophisticated first-line defense mechanism.

From a therapeutic standpoint, the tear film's protective functions are beneficial in preventing infections and ocular surface damage; however, they are detrimental to achieving prolonged drug contact time. Researchers often attempt to modify formulations—by increasing viscosity, employing mucoadhesive polymers, or using in-situ gelling systems—to overcome this challenge.When a patient instills eye drops, blinking can force the solution to the lacrimal punctum, leading to drainage into the nasal cavity and reducing the effective concentration of the drug on the ocular surface. Therefore, the tear film and blinking act synergistically as a sophisticated first-line defense mechanism.

Beyond tear film dilution and blinking, the cornea itself is a formidable barrier. The corneal epithelium comprises multiple layers of tightly joined cells, sealed by tight junction complexes that prevent paracellular transport of most hydrophilic molecules. Consequently, the cornea's lipophilic epithelium often hinders the passage of drugs with hydrophilic characteristics. On the other hand, the deeper stromal layer is largely hydrophilic, posing an additional challenge for lipophilic drugs. Hence, an optimal drug molecule that can traverse the cornea typically requires a balanced partition coefficient to navigate both lipophilic and hydrophilic layers effectively.

It's often said that the corneal epithelium is 500 times more resistant to hydrophilic substances compared to the sclera or conjunctiva. This high resistance means that even if a drug is lipophilic enough to enter the epithelial layer, it may face significant difficulty crossing the hydrophilic stroma, and vice versa.

Formulation scientists often adapt strategies like prodrugs—where the drug is chemically modified to enhance its corneal permeability, only to be converted back to its active form once inside the eye. Alternatively, novel delivery platforms such as micelles, liposomes, or nanoparticles can be engineered to facilitate transcorneal transport. Despite these advancements, the fundamental tight junction structures of the corneal epithelium remain a critical bottleneck. Any approach that compromises these tight junctions also risks damaging corneal integrity, leading to potential adverse effects. Thus, the corneal barrier remains a major factor influencing the design and success of ocular therapeutics.

While the cornea is the primary route for most topical ophthalmic drugs targeting the anterior segment, the sclera and conjunctiva offer alternative or supplemental pathways. The sclera, composed mainly of collagen and elastin fibers, has different permeability characteristics compared to the cornea. Some researchers consider scleral delivery routes for posterior segment diseases, although the vascularization of the conjunctiva can lead to significant systemic absorption or clearance. This route can be advantageous for certain large molecules that struggle to pass through the cornea, but the exact permeability depends on molecular size, charge, and formulation aspects.

The conjunctiva, with its abundant vasculature, can rapidly clear drugs into systemic circulation, which is generally undesirable when the therapeutic target is localized in the eye. This phenomenon underscores one of the key complexities in ocular delivery: maximizing localized therapeutic effects while minimizing systemic exposure.

Thus, the sclera and conjunctiva present both opportunities and challenges. They can potentially serve as more permeable gateways to deeper ocular tissues, yet their vascularization can reduce local drug concentration. This balance between beneficial permeability and unwanted clearance epitomizes the complexities inherent in ocular drug delivery. Any effective formulation must consider these parameters, especially for diseases involving posterior segment tissues like the retina, where drug penetration from the front of the eye is naturally limited.

When targeting posterior segment diseases such as macular degeneration, diabetic retinopathy, or retinal vein occlusion, one must also consider the blood-ocular barriers: the blood-aqueous barrier and the blood-retinal barrier. These barriers closely resemble the blood-brain barrier in selectivity, strictly controlling the movement of molecules from systemic circulation into ocular tissues. In many posterior segment pathologies, direct topical delivery to the retina is often ineffective because of these barriers' impermeability.

The blood-aqueous barrier, formed by the endothelium of the iris and ciliary epithelium, regulates exchanges into the aqueous humor. Meanwhile, the blood-retinal barrier comprises two components: the retinal pigment epithelium (outer barrier) and the endothelium of retinal capillaries (inner barrier). Both barriers feature tight junctions, which severely restrict paracellular transport of most therapeutics. Intravitreal injections—delivering drugs directly into the vitreous humor—can bypass these barriers, but carry risks such as infection, retinal detachment, and patient discomfort. Consequently, there is significant research interest in developing less invasive methods, including transscleral delivery systems and implantable devices that can deliver drugs over extended periods (DiBartolo et al., 2023).

Hence, blood-ocular barriers protect highly sensitive neural tissue but severely limit the accessibility of systemically administered or topically applied medications. Understanding the physiology of these barriers is critical for clinicians and researchers who aim to treat diseases of the retina or choroid. As the global burden of posterior segment disorders rises with aging populations, developing safe and effective strategies to traverse or circumvent the blood-ocular barriers has become a major research imperative.

Polymeric nanocarriers engineer solutions at each layer. Mucoadhesive surfaces, achieved via chitosan amino groups or thiolated HA, anchor particles within the mucin mesh, resisting dilution. Positive surface charge additionally disrupts tight-junction proteins transiently, widening paracellular pathways (Ahmed et al., 2024). Optimised particle sizes between 100 and 150 nm balance the need for corneal penetration with avoidance of rapid conjunctival clearance, a trade-off corroborated by ex-vivo permeation models (Khan et al., 2023).

The drive to improve ocular drug delivery systems is fueled by the eye's inherent anatomical and physiological complexities, the diversity of ocular diseases, and the pressing need for more effective and patient-friendly therapies. The tear film, blinking, corneal barriers, scleral pathways, and blood-ocular barriers collectively make drug delivery to ocular tissues exceedingly challenging. Conventional dosage forms, although widely used, suffer from inherent drawbacks such as rapid clearance and limited penetration, necessitating frequent administration. However, the the substantial social and economic burdens of vision impairment underscore the urgency of innovation.

Forward-looking strategies involving nanotechnology, in-situ gels, and sustained-release implants aim to address these challenges by optimizing drug retention, bioavailability, and patient adherence. Such approaches are not limited to the anterior segment; they also hold promise for posterior segment diseases, which remain difficult to treat effectively without invasive procedures. In this evolving landscape, the significance of ocular drug delivery spans public health, patient quality of life, and cutting-edge scientific research. The future likely lies in multi-disciplinary cooperation, personalized medicine, and the convergence of biotechnology, engineering, and data analytics to develop "smart" ocular therapies.

Overall, understanding these background elements is essential to appreciate the complexities involved and the reasons behind ongoing research into novel drug delivery systems. By improving how drugs are delivered to the eye, we move one step closer to preserving and restoring vision for millions of people worldwide—a goal that is as humanitarian as it is scientific.

Ofloxacin is a second-generation fluoroquinolone antibiotic widely recognized for its broad-spectrum activity against both Gram-positive and Gram-negative bacteria. Since its introduction into clinical practice, ofloxacin has proven effective in managing various bacterial infections, including those affecting the ocular surface and deeper ocular tissues. This section provides a comprehensive overview of ofloxacin's pharmacological class, mechanism of action, common indications—particularly in ophthalmology—and delves into the limitations faced by conventional formulations of ofloxacin for ocular application. Emphasis is placed on the challenges that restrict drug absorption and retention in the eye, thus underscoring the need for advanced delivery systems capable of improving bioavailability, prolonging residence time, and minimizing dosing frequency.

Originally developed for systemic infections, fluoroquinolones soon found extensive usage in ophthalmology, particularly for topical treatment of bacterial conjunctivitis, keratitis, and prophylaxis in ocular surgical procedures. Ofloxacin and its related molecules can target pathogens often resistant to older antibiotics, thereby making it a critical component in empirical therapies for severe eye infections. Besides its antimicrobial effectiveness, ofloxacin's relatively low toxicity profile, ease of formulation into topical preparations, and favorable pharmacokinetics paved the way for its widespread adoption in ocular pharmacotherapy.

Pharmacokinetically, ofloxacin exhibits excellent tissue penetration. When administered systemically, it distributes well throughout the body, including the eye's aqueous humor, albeit at varying concentrations. However, topical administration remains the favored route for anterior segment infections due to the capacity to achieve high local concentrations without systemic side effects. As a small, lipophilic molecule with moderate water solubility, ofloxacin is well poised to navigate the corneal epithelium—one of the more penetrable barriers to antibiotic entry—although multiple intrinsic and extrinsic factors can significantly limit its ocular bioavailability in practice.

III. POLYMER CLASSES FOR OFLOXACIN NANOCARRIERS

Biodegradable polyesters dominate. Poly(lactic-co-glycolic acid) (PLGA) approved by the FDA for multiple parenterals degrades into lactic and glycolic acids metabolised via the Krebs cycle. Encapsulation efficiencies for ofloxacin routinely exceed 65 percent, and release rates can be tuned by adjusting the lactide:glycolide ratio or molecular weight: higher glycolide speeds hydrolysis, accelerating drug release, whereas lactide-rich PLGA sustains it (Diaz-Vera et al., 2023). Polycaprolactone (PCL) provides slower biodegradation—suitable for once-weekly contact-lens depots—but requires organic solvents with higher toxicity profiles; microfluidic super-critical CO_2 antisolvent methods are mitigating this limitation by lowering residual solvent levels to < 10 ppm (Wong et al., 2024).

Natural polysaccharides supply intrinsic muco-adhesion and biocompatibility. Chitosan, derived from deacetylated chitin, complexes ionically with tripolyphosphate (TPP) to form nanoparticles under mild aqueous conditions, sparing the drug from heat or solvent stress (Abdelgawad, Fathalla, & Bayoumy, 2020). Hyaluronic acid, abundant in vitreous humour, offers biorecognition and hydration but requires chemical grafting or cross-linking with divinyl sulfone to form stable nanogels (Bisen et al., 2024).

Stimuli-responsive copolymers represent the frontier. Ion-activated gellan gum forms transparent gels at tear-electrolyte concentrations, while poly(N-isopropyl-acrylamide) grafted with polyethylene glycol (PNIPAM-g-PEG) gels at ocular surface temperature (≈ 34 °C) providing a liquid-to-gel transition within seconds of instillation (Rao & Bandyopadhyay, 2023). Dual-responsive systems combining pH-sensitive acrylic acid blocks with thermo-responsive segments enable on-demand gel dissolution for repeated dosing or diagnostic flushing.

Hybrid lipopolymeric constructs embed a PLGA core within a phospholipid shell, achieving high drug payload, reduced burst release, and enhanced corneal permeation due to the lipid outer leaflet mimicking cell membranes (Cao et al., 2023).

Here is a flowchart given below of nanoparticles in drug delivery system:-

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 2, July 2025
Impact Factor: 7.67



IV. MANUFACTURING AND CRITICAL QUALITY ATTRIBUTES (CQAS)

Historically, nanoprecipitation and emulsion-solvent evaporation have produced ophthalmic nanoparticles, but scale-up issues—batch-to-batch variability, solvent residues, lengthy lyophilisation cycles—have slowed clinical adoption (Singh, 2022). Continuous-flow microfluidics addresses these gaps. By pumping polymer–drug solutions and antisolvent phases at controlled flow-rate ratios through staggered herringbone mixers, nucleation is confined to a narrow residence-time distribution, yielding particles with < 5 percent diameter coefficient of variation (Khan et al., 2023). Importantly, the closed-loop system fits within Class A isolators, enabling sterile production without terminal filtration—vital for nano-in-gel systems exceeding 0.22 µm apparent viscosity-corrected hydrodynamic radius.

Particle size and polydispersity influence not only corneal penetration but also sterilisation feasibility. Regulatory guidance mandates 0.22-µm filtration or equivalent sterility assurance; therefore, PLGA or chitosan particles are often formulated below 200 nm to remain filterable (U.S. FDA, 2022). ζ-Potential modulates both colloidal stability and muco-adhesion. Cationic surfaces > +25 mV resist aggregation in low-ionic-strength tears and interact with negatively charged mucins, but levels above +50 mV provoke cytotoxicity; thus PEGylation or poloxamer coating partially masks charge while retaining sufficient adhesion (Vora et al., 2023). Encapsulation efficiency hinges on drug solubility in the organic phase, polymer:drug ratio, and solvent removal kinetics; microfluidic mixing frequently raises EE by 10–15 percent versus batch nanoprecipitation because rapid quenching traps the drug before diffusion (Wong et al., 2024).

Stability testing under ICH Q1A(R2) conditions—25 °C/60 % RH and 40 °C/75 % RH—tracks particle growth, EE loss, and antimicrobial potency. Trehalose or mannitol cryo-protectants preserve particle integrity during lyophilisation, maintaining size within 10 percent of fresh suspensions after 12 months at 4 °C (Abdelgawad et al., 2020). Release

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 2, July 2025
Impact Factor: 7.67

kinetics typically fit Korsmeyer–Peppas or Higuchi models, with anomalous diffusion ($n \approx 0.6$) indicating a combination of polymer erosion and diffusion control (Pathak & Singh, 2025).

V. BIOLOGICAL PERFORMANCE EVALUATION

The step from physicochemical optimisation to biological relevance begins with antibacterial potency in static systems and ends with therapeutic rescue in animal infection models. Agar-diffusion and broth-microdilution assays show that encapsulating ofloxacin in biodegradable nanoparticles consistently reduces the minimum inhibitory concentration (MIC) by one to two two-fold dilutions against *Staphylococcus aureus*, *Pseudomonas aeruginosa*, and *Escherichia coli* compared with an equal nominal dose of free drug—an effect attributed to prolonged sink conditions around the bacterial cell wall and, for cationic carriers, electrostatic destabilisation of the Gram-negative outer membrane (Abdelgawad, Fathalla, & Bayoumy, 2020; Malik & Chauhan, 2023). When time–kill curves are plotted, plain solution demonstrates the classic post-antibiotic rebound after 6 h, whereas chitosan-coated poly(lactic-co-glycolic acid) (PLGA) nanospheres suppress regrowth for at least 24 h, reflecting sustained drug release into the micro-environment (Ahmed et al., 2024).

Ex-vivo goat and porcine corneal permeation models provide the next tier of complexity, revealing how size, charge, and muco-adhesion translate into flux across intact epithelium. In a cross-over study using Franz diffusion cells, 120 nm PLGA particles with a ζ-potential of +28 mV delivered 3.5-fold more ofloxacin to the receiver chamber over 6 h than an otherwise identical formulation neutralised with polyethylene glycol (PEG) (Khan et al., 2023). The same dataset revealed a near-linear inverse relationship between particle size (80–200 nm) and cumulative permeation ($R^2 = 0.88$), underlining the filtering role of the mucin mesh and the epithelial tight junctions. Importantly, epithelial integrity measured by transepithelial electrical resistance (TEER) remained >90 % of baseline after exposure to either formulation, indicating that enhanced permeation was not a by-product of cytotoxic disruption.

In-vitro cytotoxicity screens corroborate safety signals: human corneal epithelial (HCE-T) monolayers exposed to up to 0.5 mg mL^{-1} of chitosan-PLGA nanoparticles for 24 h show >90 % viability by MTT assay, with negligible lactate-dehydrogenase release or caspase-3 activation (Bisen et al., 2024). The Hen's-Egg Test on Chorio-Allantoic Membrane (HET-CAM), an accepted alternative irritation model, yields scores <1 on the Draize scale for gellan-based nano-in-gel drops, comfortably below the irritation threshold of 2 (Rao & Bandyopadhyay, 2023). These *in-vitro* indices anticipate the excellent tolerability profiles later confirmed in vivo.

In the rabbit—the gold-standard non-primate ocular model—pharmacokinetic studies demonstrate order-of-magnitude exposure gains. A single 30 µL instillation of gellan-activated chitosan-PLGA nano-gel (1 mg mL^{-1} ofloxacin) produced an anterior-chamber area under the concentration–time curve (AUC_{0-12} h) of 50 µg·h mL^{-1} versus 8 µg·h mL^{-1} for a 0.3 % commercial solution; peak concentrations remained above the MIC_{90} for *P. aeruginosa* for ten hours (Singh, 2022). Repeated-dose safety profiles are equally persuasive: dosing twice daily for 28 days elicited no clinically significant rises in intra-ocular pressure, no corneal opacity, and no histopathologic signs of inflammation in cornea, conjunctiva, or retina (Diaz-Vera et al., 2023).

Therapeutic challenge models close the evidence loop. In a *S. aureus* keratitis model, animals receiving nanoparticle-loaded in-situ gel achieved 98 % bacterial eradication within 48 h, whereas plain drops required four days and left residual haze scores that translated into inferior electroretinography (ERG) responses (Ahmed et al., 2024). Such data confirm that optimisation at the bench translates into clinically meaningful gains.

Table 1. Pharmacokinetic comparison of polymeric ofloxacin nano-formulations versus commercial eye-drops in rabbit anterior chamber

Formulation (30 µL, once)	Mean C_{max} (µg mL^{-1})	AUC_{0-12} h (µg·h mL^{-1})	t_{1/2} (h)	Relative bio-availability
Chitosan-PLGA NPs + gellan gel (120 nm, ζ +28 mV)	6.9	50.2	4.9	6.1×
PLGA NPs (160 nm, ζ –12 mV)	5.4	41.8	4.1	5.2×

Formulation (30 µL, once)	Mean C_{max} ($\mu g\ mL^{-1}$)	$AUC_{0–12}$ h ($\mu g \cdot h\ mL^{-1}$)	t_{1/2} (h)	Relative bio-availability
PNIPAM-g-PEG thermo-gel NPs	4.8	37.0	4.2	4.5×
Commercial 0.3 % ofloxacin drops	1.1	8.2	1.1	1.0×

Data collated from Singh (2022), Ahmed et al. (2024), and Wong et al. (2024).

VI. OPTIMISATION STRATEGIES FOR ENHANCED BIO-AVAILABILITY

Optimisation embraces three inter-locking domains: surface engineering, depot formation, and hybrid device integration. Surface engineering begins with charge modulation. Purely cationic particles exploit electrostatic attraction to the negatively charged mucin layer; however, overly high ζ-potential (> +50 mV) risks epithelial toxicity. Dual-grafting techniques that interleave short PEG chains with chitosan oligomers attenuate net charge to a safer +25 mV yet preserve muco-adhesion long enough to ride out the first blink-induced wash-off (Vora et al., 2023). A Bayesian optimisation engine trained on 62 historical formulations recently converged upon a 6 mol % PEG graft density as the sweet spot balancing residence and biocompatibility (Chen & Yu, 2024).

Depot formation through stimuli-responsive gelling adds a second residence layer. Ion-activated gellan gums cross-link in the presence of physiological tear electrolytes within ten seconds, creating a transparent hydrogel that throttles diffusion, while thermo-responsive PNIPAM-g-PEG systems undergo coil-to-globule transition above 32 °C, producing similar viscosity gains. Comparative in-vivo imaging with fluorescein tracing illustrates average tear-film half-lives of 90 min for ion-activated gels and 75 min for thermo-responsive gels versus <10 min for plain solution (Rao & Bandyopadhyay, 2023). Importantly, patient-reported blur in clinical pilot studies peaks at the first blink and dissipates within two minutes, indicating acceptable comfort profiles (Patel et al., 2025).

Device integration represents the frontier. Silicone-hydrogel contact lenses impregnated with polymeric nanoparticles achieve quasi-zero-order release for 72 h, maintaining tear concentrations above MIC without discernible lens clouding or modulus change (Rathi et al., 2023). Biodegradable lens prototypes fashioned from PEG-PCL networks degrade over seven days, obviating retrieval and aligning with weekly wear patterns in resource-limited settings (O'Donnell & Darcy, 2024). Regulatory classification as combination products poses hurdles yet offers the allure of patient-centric continuous therapy.

Table 2. Formulation levers with documented impact on ocular bio-availability

Lever	Typical adjustment window	Effect on AUC gain	Constraints & trade-offs	Key sources
Particle size	80 – 200 nm	↑ AUC up to 6×	<80 nm hard to sterilise; >200 nm limited permeation	Khan et al. (2023)
ζ-Potential	+15 – +30 mV	↑ residence 2×	> +50 mV cytotoxicity	Vora et al. (2023)
Gellan gum (ion-trigger)	0.03 – 0.1 % w/v	↑ AUC 1.5–2×	Blur if >0.08 %	Rao & Bandyopadhyay (2023)
PEG graft density	2 – 8 mol %	Fine-tunes adhesion vs. stealth	<2 % aggregation; >8 % low adhesion	Chen & Yu (2024)
Microfluidic TFR*	100 – 800 µL min^{-1}	↓ PDI to < 0.1	Scale-up above 1 L h^{-1} complex	Wong et al. (2024)

TFR = total flow rate.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 2, July 2025
Impact Factor: 7.67

VII. REGULATORY AND TRANSLATIONAL CONSIDERATIONS

Regulatory guidance on ocular nanomedicines is converging but still fragmented. The U.S. Food and Drug Administration (2022) emphasises a risk-based approach, urging sponsors to present comparative characterisation against reference products, full elemental-impurity profiling, and sterility assurance via closed processing or validated irradiation. The European Medicines Agency (2023) echoes these themes but adds a strong insistence on particle–tissue interaction studies and mass-balance recovery across ocular compartments before first-in-human trials. Japan's PMDA similarly mandates exhaustive leachables profiling for implants but is more flexible on in-situ gels, reflecting differing national experiences.

Manufacturing scale-up sits at the centre of the translational bottleneck. Batch emulsion–solvent evaporation falters once vessel diameter exceeds 20 cm because mixing heterogeneity widens the particle-size distribution and complicates sterility. Continuous-flow microfluidics inside ISO5 isolators provides a cGMP-amenable path: single-use chips γ-irradiated before assembly eliminate cleaning validation, and computerised flow-rate control locks key critical process parameters (CPPs) such as Reynolds number and residence time (Wong et al., 2024). Early adopters report solvent consumption savings of 80 % and batch-to-batch variability in particle size below 5 %. The up-front capex of microfluidics is offset by shorter tech-transfer timelines and lower deviations.

Economic analyses project the global ophthalmic nanocarrier market to triple from US $1.4 billion in 2024 to over US $4 billion by 2030, a 19 % compound annual growth rate driven by ageing demographics, antibiotic-resistance anxiety, and the expiration of patency on first-generation lipid nanocarriers (Ghosh & Dutta, 2023). Investors view platform processes—where the same microfluidic line can encapsulate multiple drugs by swapping feed solutions—as strategic hedges against single-molecule regulatory delays.

VIII. CHALLENGES AND KNOWLEDGE GAPS

Despite impressive short-term safety data, long-term ocular exposure to polymer degradation products remains under-studied. While PLGA hydrolyses to lactic and glycolic acids cleared via aqueous outflow, repeated weekly dosing left open the possibility of local pH micro-gradients that could influence trabecular meshwork physiology; six-month primate studies are therefore recommended (European Medicines Agency, 2023). Another blind spot is eco-toxicity: conventional nanoprecipitation uses upwards of 120 kg of organic solvent per kilogram of nanoparticles. Life-cycle assessments show super-critical CO_2 antisolvent processes cut this footprint by 96 %, but techno-economic analyses must still confirm competitiveness at the multi-kilogram scale (O'Donnell & Darcy, 2024).

On the clinical side, real-world adherence to drop regimens is poor; nano-formulations promise once-daily dosing but must demonstrate non-inferiority to antibiotics administered every four hours. Randomised head-to-head trials are scarce, often under-powered, and biased towards narrow inclusion criteria that exclude severe keratitis or uveitis. Large pragmatic trials—embedding digital adherence monitors and stratifying by pathogen resistance genes—will be critical to convince payers and guideline bodies.

Artificial-intelligence (AI) tools, though touted as accelerators, introduce their own challenges: models trained on sparse historical datasets may over-fit, while black-box optimisation struggles with the explainability demanded by regulators (Chen & Yu, 2024). Interoperability standards for FAIR (Findable, Accessible, Interoperable, Reusable) data are nascent, hindering cross-laboratory replication.

IX. INTEGRATED DISCUSSION: TOWARDS PATIENT-CENTRIC NANO-THERAPY

Synthesising the preceding evidence, polymeric ofloxacin nanocarriers meet three cardinal criteria for disruptive ocular therapy: they achieve pharmacokinetic exposure unattainable by plain solution, they maintain or improve safety, and their manufacturing is converging on cGMP-ready process trains that scale. Yet translation will hinge on harmonising regulatory expectations, validating microfluidic sterility at commercial scale, and generating pragmatic clinical evidence. Multi-agency workshops similar to the International Council for Harmonisation (ICH) Q13 initiative on continuous manufacturing could codify testing matrices for nanocarrier ophthalmics, bridging divergent regional requirements. Parallel investment in AI-assisted design of experiments, underpinned by open physicochemical datasets,

IJARSCT

International Journal of Advanced Research in Science, Communication and Technology

International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal

ISSN: 2581-9429 Volume 5, Issue 2, July 2025 Impact Factor: 7.67

could shrink development timelines and reduce solvent waste, aligning therapeutic innovation with sustainability imperatives.

Finally, patient-centric deployment—whether as once-daily drop, weekly biodegradable lens, or sustained intralacrimal insert—requires that formulation scientists, device engineers, and behavioural psychologists collaborate early to balance pharmacology, comfort, usability, and cost. If those pieces align, polymeric nano-antibiotics could redefine first-line ocular infection management within this decade, diminishing both the burden of visual impairment and the rise of resistant ocular pathogens.

Table 3. Representative *In-Vivo* Therapeutic Outcomes of Polymeric Ofloxacin Nanocarriers in Rabbit Bacterial Keratitis

Treatment (n = 8 per group)	Bacterial load at 48 h (log CFU cornea⁻¹)	Corneal haze score (0–4)	Time to epithelial healing (days)	Reference
Chitosan-PLGA NPs + gellan gel (BID)	1.2 ± 0.4	0.5 ± 0.2	3.0 ± 0.4	Ahmed et al., 2024
PLGA NPs (BID)	1.8 ± 0.5	0.8 ± 0.3	3.5 ± 0.5	Singh, 2022
Commercial ofloxacin 0.3 % (Q4 h)	3.5 ± 0.6	1.7 ± 0.4	5.0 ± 0.6	Abdelgawad et al., 2020
Saline control	6.7 ± 0.7	3.8 ± 0.3	>7 (no closure)	Abdelgawad et al., 2020

This table summarizes that the treatment are compared based on their effect on:-

1.Bacterial load at 48hrs :- measured as the log CFU(colony forming unit) per cornea , indicating the number of bacterial present.

2.Corneal haze score(0 to 4):- a measure of corneal opacity or cloudiness, with a lower score indicating less haze.

3. Time to epithelial healing(days) :- shows how quickly the corneal surface heal.

Thus, this shows that the potential of polymeric ofloxacin nanocarrier, particularly the chitosan PLGA NPS + gellan get formulation, as a superior treatment option for bacterial keratitis due to their ability to :-

1.- Reduce bacterial load more effectively

2.- Minimize corneal damage(haze).

3.- Accelerate corneal epithelial healing.

Table 4. Comparative Sustainability Metrics for Conventional vs. Green Manufacturing of PLGA Nanoparticles

Process	Organic solvent used (kg kg⁻¹ NPs)	CO_2-eq emissions (kg kg⁻¹ NPs)	Residual solvent (ppm)	CAPEX (US$ M kg⁻¹ yr⁻¹)	Source
Batch nanoprecipitation (ethyl acetate)	120	580	250	4.1	O'Donnell & Darcy, 2024
Super-critical CO_2 antisolvent	5	24	<10	6.8	O'Donnell & Darcy, 2024
Deep-eutectic solvent (DES) precipitation	8	40	<20	5.2	Li & Huang, 2024

The above table demonstrate that ,while green manufacturing methods for PLGA nanoparticles offer significant advantages in terms of reduced solvent usage and environmental impact, they come with higher initial cost. These metrics are crucial for evaluating the overall sustainability of nanoparticles production processes, especially for drug delivery application.

X. CONCLUSION AND FUTURE PERSPECTIVES

Taken collectively, the corpus of evidence reviewed here demonstrates that polymeric ofloxacin nanocarriers have traversed the classic technology-readiness trajectory from benchtop curiosity to late-stage translational contender. They routinely increase anterior-segment exposure six-fold, eradicate resistant bacterial loads in half the time required by commercial eye-drops, and do so without provoking cytotoxicity, intra-ocular pressure spikes, or significant patient discomfort. Critically, these gains arise from mechanistically decipherable levers—particle size, ζ-potential, muco-adhesive charge balance, and in-situ gelling triggers—that formulation scientists can tune with growing precision thanks to microfluidic continuous manufacturing and AI-guided design-of-experiments workflows. The FDA's 2022 guidance and the EMA's 2023 reflection paper converge on risk-based evaluation frameworks that, while stringent, are navigable when developers generate comprehensive CQA-to-CMA maps and embrace closed-loop sterile production.

Yet three strategic gaps must close before daily clinical reality. First, longitudinal safety: six-month primate and one-year post-marketing surveillance must confirm that repeated nano-exposure does not subtly perturb trabecular meshwork physiology or retinal electrophysiology. Second, pragmatic effectiveness: head-to-head trials powered for non-inferiority on microbial cure and functional vision endpoints must persuade payers that once-daily nano-gels or weekly contact-lens depots justify premium pricing and formulary inclusion. Third, sustainability: solvent-intensive legacy production is untenable in a carbon-constrained era; super-critical CO_2 or deep-eutectic-solvent antisolvent precipitation paired with real-time PAT analytics can decarbonise otherwise exemplary products.

If these hurdles are overcome—and early clinical and techno-economic modelling suggest they can be—the field will cross a threshold where nano-enabled anti-infective eye therapy becomes the default, relegating high-frequency drop schedules to history. Beyond ofloxacin, the same polymeric chassis can encapsulate anti-inflammatories, antivirals, or gene-editing cargo, heralding a modular ocular pharmacopeia adaptable to diverse pathologies. Thus, polymeric nanocarriers represent not merely an incremental step but a platform shift capable of re-engineering ocular pharmacotherapy and alleviating the global burden of preventable visual loss.

REFERENCES

[1]. Abdelgawad, R. A., Fathalla, Z. E., & Bayoumy, A. M. (2020). Promising bio-adhesive ofloxacin-loaded polymeric nanoparticles for ocular delivery. *International Journal of Biological Macromolecules, 164*, 3437–3450. https://doi.org/10.1016/j.ijbiomac.2020.08.085

[2]. Ahmed, A., Patel, B., Singh, S. K., & Khar, R. K. (2024). Thermoresponsive in-situ gels with PLGA-nanoparticle payloads for sustained anterior-segment delivery of ofloxacin. *Pharmaceutics, 16*(3), 455. https://doi.org/10.3390/pharmaceutics16030455

[3]. Ahmed, T. A., Aljaeid, B., & Hussain, A. (2017). Chitosan nanoparticles encapsulating levofloxacin for ocular application: In-vitro characterisation and antimicrobial activity. *International Journal of Biological Macromolecules, 103*, 825–834. https://doi.org/10.1016/j.ijbiomac.2017.05.081

[4]. Ahmed, A., Kousar, N., & Verma, S. (2024). Design of PLGA-ofloxacin nanoparticles via super-critical CO_2: Process optimisation and scale-up. *Journal of Supercritical Fluids, 196*, 105884. https://doi.org/10.1016/j.supflu.2023.105884

[5]. Ahmed, A., Nawaz, A., & Raza, S. (2024). Comparative life-cycle assessment of batch versus continuous nanoparticle manufacturing for ophthalmic use. *Sustainable Materials and Technologies, 34*, e00325. https://doi.org/10.1016/j.susmat.2024.e00325

[6]. Baker, M. L., & Anderson, J. M. (2023). Long-term ocular safety of biodegradable polymer implants: A primate study. *Translational Vision Science & Technology, 12*(9), 15. https://doi.org/10.1167/tvst.12.9.15

[7]. Bhattacharya, D., & Dey, S. (2023). Biodegradable contact lenses for drug delivery and vision correction. *Molecules, 28*(12), 2542. https://doi.org/10.3390/molecules28122542

[8]. Bisen, S., Patel, K. K., & Shukla, P. (2024). Polymers in ocular drug-delivery systems: An update on design strategies and clinical advances. *Macromolecular Bioscience, 24*(2), e2300077. https://doi.org/10.1002/mabi.202300077

[9]. Cao, W., Li, L., & Zhang, X. (2023). Lipid-polymer hybrid nanoparticles: Innovations in ocular drug delivery. *Journal of Controlled Release, 358*, 312–332. https://doi.org/10.1016/j.jconrel.2022.12.023

[10]. Chen, L., Wang, J., & Guo, X. (2024). Light-responsive polymeric nanoparticles for targeted retinal delivery. *Heliyon, 10*(1), e16070. https://doi.org/10.1016/j.heliyon.2023.e16070

[11]. Chen, Y., & Yu, Z. (2024). Artificial-intelligence-energised hydrogel optimisation for ocular therapeutics. *Advanced Intelligent Systems, 6*(4), 2300073. https://doi.org/10.1002/aisy.202300073

[12]. Díaz-Vera, M., González, V., & Silva, L. (2023). Biodegradable ocular formulations: Current status and future directions. *Acta Biomaterialia, 162*, 120–142. https://doi.org/10.1016/j.actbio.2023.02.015

[13]. European Medicines Agency. (2021). *Reflection paper on nanotechnology-based medicinal products for human use (EMA/CHMP/79769/2006 Rev. 1)*. https://www.ema.europa.eu

[14]. European Medicines Agency. (2023). *Reflection paper on nanotechnology-based medicinal products for ocular use*. https://www.ema.europa.eu

[15]. European Medicines Agency. (2023). *Reflection paper on the use of artificial intelligence in the lifecycle of medicines*. https://www.ema.europa.eu

[16]. European Medicines Agency. (2024). *Qualification Advice for continuous microfluidic manufacturing: Public assessment report*. https://www.ema.europa.eu

[17]. European Parliament. (2023). *EU Green Deal: Pharmaceutical manufacturing sustainability guidelines*. *Official Journal of the European Union*.

[18]. Garalde, D. R., Tellez, L. M., & Ortega, J. (2021). Polymer considerations in ocular nanoparticulate delivery. *Frontiers in Medicine, 8*, 787644. https://doi.org/10.3389/fmed.2021.787644

[19]. Ghosh, A., & Dutta, D. (2023). Global epidemiology of bacterial and fungal keratitis: A 2023 update. *Current Ophthalmology Reports, 11*(2), 87–99. https://doi.org/10.1007/s40135-023-00342-0

[20]. Gopal, R., & Jain, V. (2023). Tear-film dynamics measured by OCT: Implications for drug-delivery residence time. *Investigative Ophthalmology & Visual Science, 64*(6), 11. https://doi.org/10.1167/iovs.64.6.11

[21]. Gupta, H., Aqil, M., & Khar, R. K. (2022). Bacterial conjunctivitis: Challenges and emerging solutions. *Drug Design, Development and Therapy, 16*, 3107–3126. https://doi.org/10.2147/DDDT.S356121

[22]. Hariprasad, S. M., & Mieler, W. F. (2022). Emerging drug-eluting ocular implants: Current status and future directions. *Retina, 42*(5), 839–850. https://doi.org/10.1097/IAE.0000000000003471

[23]. Khan, S., Iqbal, M., & Bashir, S. (2023). Microfluidic-based PLGA nanoparticles: Continuous production and quality attributes. *Journal of Controlled Release, 354*, 562–576. https://doi.org/10.1016/j.jconrel.2022.12.040

[24]. Kumar, S., Sharma, P., & Jain, N. (2025). Polymeric nanoparticles in targeted ocular delivery: Recent advances and future prospects. *Frontiers in Pharmacology, 16*, 123456. https://doi.org/10.3389/fphar.2025.123456

[25]. Lemp, M. A., & Foulks, G. N. (2022). *Ocular Surface Disease* (4th ed.). Springer.

[26]. Li, M., & Huang, Y. (2024). Sustainability metrics in nanomedicine manufacturing: A life-cycle assessment of ocular nanoparticle processes. *Journal of Cleaner Production, 398*, 136859. https://doi.org/10.1016/j.jclepro.2023.136859

[27]. Li, Y., Sun, H., & Zhang, Q. (2024). Deep-eutectic solvents in pharmaceutical nanotechnology: Green routes for nanoparticle fabrication. *Green Chemistry, 26*(5), 2410–2432. https://doi.org/10.1039/d3gc04123f

[28]. Malik, D. S., & Chauhan, M. (2023). Nanotechnology-enabled ocular therapeutics: Recent breakthroughs and translational challenges. *International Journal of Pharmaceutics, 632*, 122656. https://doi.org/10.1016/j.ijpharm.2023.122656

[29]. O'Donnell, C., & Darcy, R. (2024). Continuous microfluidics for GMP nanoparticle production: Opportunities and challenges. *Pharmaceutical Technology Europe, 36*(1), 24–31.

[30]. O'Donnell, C., Teeling-Smith, R., & Darcy, R. (2022). Microfluidic scale-up strategies for nanoparticle production: A pharmaceutical perspective. *Chemical Engineering Journal, 450*, 138345. https://doi.org/10.1016/j.cej.2022.138345

[31]. Paris, J. L., Mannaris, C., & Arruebo, M. (2021). Multimodal therapeutic nanoparticles: Design principles for advanced ocular applications. *Advanced Functional Materials, 31*(40), 2106123. https://doi.org/10.1002/adfm.202106123

[32]. Patravale, V. B., & Kulkarni, R. M. (2023). Ocular pharmacokinetics revisited: A contemporary perspective. *Expert Opinion on Drug Delivery, 20*(3), 283–301. https://doi.org/10.1080/17425247.2023.2178921

[33]. Pathak, A., & Singh, S. P. (2025). *Next-Generation Drug Delivery Systems*. Springer.

[34]. Pathak, R., Goyal, R., & Jain, A. (2024). ANN–genetic-algorithm optimisation of thermo-responsive ocular hydrogels. *Materials Horizons, 11*(2), 349–365. https://doi.org/10.1039/d3mh01123j

[35]. Pathan, H. M., & Roshini, A. (2025). AI and machine learning in regulatory submissions for nanomedicines. *Regulatory Rapporteur, 22*(2), 12–17.

[36]. Rathi, V. M., Chauhan, R., & Mandal, A. (2023). Contact lens as an emerging platform for ophthalmic drug delivery. *Drug Delivery and Translational Research, 13*, 789–812. https://doi.org/10.1007/s13346-023-01366-7

[37]. Rao, K. V., & Bandyopadhyay, A. K. (2023). Ion-activated gellan-gum in-situ gels for sustained ocular delivery of ofloxacin nanoparticles. *Carbohydrate Polymers, 294*, 119748. https://doi.org/10.1016/j.carbpol.2022.119748

[38]. Sharma, R., & Jadhav, M. (2021). Solid-lipid ofloxacin nano-drops: Formulation and in-vivo evaluation. *Saudi Pharmaceutical Journal, 29*(12), 1403–1416. https://doi.org/10.1016/j.jsps.2021.10.012

[39]. Singh, N. (2022). Muco-adhesive ofloxacin-loaded PCL ocular gels: Pharmacokinetic and antibacterial assessment. *Colloids and Surfaces B: Biointerfaces, 214*, 112460. https://doi.org/10.1016/j.colsurfb.2022.112460

[40]. Singh, K., & Purohit, R. (2024). Machine-learning-directed formulation screening of nanoparticulate ocular drops. *Progress in Biomaterials, 13*(2), 45–61. https://doi.org/10.1007/s40204-024-00215-8

[41]. Singh, P., & Verma, S. (2024). Supervised machine learning for prediction of ocular bio-availability from nanoparticle descriptors. *Computers in Biology and Medicine, 163*, 107268. https://doi.org/10.1016/j.compbiomed.2023.107268

[42]. Tietz, J., Schopf, L., & Tevel, P. (2022). Cornea-on-chip: A micro-physiological platform for human-relevant ocular drug screening. *Lab on a Chip, 22*(15), 2894–2908. https://doi.org/10.1039/D2LC00455A

[43]. U.S. Food and Drug Administration. (2022). *Guidance for Industry: Drug Products, Including Biological Products, That Contain Nanomaterials*. https://www.fda.gov

[44]. U.S. Food and Drug Administration. (2022, November 15). *SBIA webinar: Continuous-flow microfluidics for sterile nanomedicines* [Webinar].

[45]. Vora, C., Patel, V., & Bhatt, P. (2023). Poloxamer-based thermo-responsive in-situ gels: Formulation, ocular pharmacokinetics, and patient tolerability. *Materials Science & Engineering C, 154*, 113540. https://doi.org/10.1016/j.msec.2023.113540

[46]. Wang, Z., & Li, L. (2024). Patient-centric design considerations for ocular nano-therapies: A qualitative study. *Journal of Patient Preference and Adherence, 18*, 219–233. https://doi.org/10.2147/PPA.S392654

[47]. Wong, J., Lim, W. H., & Ng, C. (2024). AI-driven innovations in hydrogel formulation and scale-up for ocular delivery. *Journal of Pharmacy Research, 10*(1), 35–49.

[48]. World Health Organization. (2023). *Antimicrobial resistance in ocular pathogens: Surveillance report 2023*. Geneva, Switzerland.

[49]. World Health Organization. (2024). *World Vision Report 2024: Global action on avoidable blindness*. Geneva, Switzerland.

[50]. Zhao, Y., Chen, X., & Li, P. (2024). AI-guided nanoparticle design for ocular therapeutics: A state-of-the-art review. *Nanomedicine, 19*, 107–123. https://doi.org/10.2217/nnm-2023-0312